Global Oncology Academy

Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Project Oncology®
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
- Charles Turck, PharmD, BCPS, BCCCP
- Hannah McManus, MD
- Andrew Armstrong, MD, MSc
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
CME/CE Live Broadcast
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
December 18, 2024
12:00 PM - 01:30 PM ET
1.50 credits Learn more
Developments in Colorectal Cancer Screening: Cell-Free DNA Blood Testing
Developments in Colorectal Cancer Screening: Cell-Free DNA Blood Testing
GI Insights
Developments in Colorectal Cancer Screening: Cell-Free DNA Blood Testing
- Peter Buch, MD, FACG, AGAF, FACP
- William Grady, MD
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
Project Oncology®
How PSMA Scans Inform Metastatic Prostate Cancer Diagnosis and Treatment
- Daniel Kwon, MD
CME/CE Meeting
HER2+ Advanced Solid Tumors: A Fireside Chat on Harnessing Molecular Profiling to Improve Patient Outcomes
December 08, 2024
Singapore
1.50 credits Learn more
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
MinuteCE®
High-Risk, HR+/HER2- EBC: Mastering Treatment Selection
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
MinuteCE®
Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
MinuteCE®
Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits

Medical News

Medical News
AI-Driven Tool Offers Contactless Screening for Hypertension and Diabetes
newsroom.heart.org
11/20/2024
Read more
Medical News
Mohs Surgery Matches Wide Excision in Effectiveness for Lentigo Maligna Melanoma, Study Shows
practicaldermatology.com
11/20/2024
Read more
Medical News
Digital Health Technologies Drive Advances in Diabetes Prevention and Management
pbrc.edu
11/20/2024
Read more
Medical News
PSC Without IBD Linked to Elevated Colorectal Cancer Risk, New Findings Show
emjreviews.com
11/20/2024
Read more

See more news

CME/CE

Interprofessional Coordination of Adverse Event Management
Interprofessional Coordination of Adverse Event Management
MinuteCE®
Interprofessional Coordination of Adverse Event Management
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Treatment Intensification in HR+/HER2- EBC: Who and When?
Treatment Intensification in HR+/HER2- EBC: Who and When?
MinuteCE®
Treatment Intensification in HR+/HER2- EBC: Who and When?
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Recent updates from adjuvant trials in HR+/HER2- EBC
Recent updates from adjuvant trials in HR+/HER2- EBC
MinuteCE®
Recent updates from adjuvant trials in HR+/HER2- EBC
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
MinuteCE®
Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits

Clinical Practice

Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CE
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
0.25 credits
- Joyce O'Shaughnessy, MD
0.25 credits
MinuteCE®
Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer
1.25 credits 10 episodes
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 credits 10 episodes
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
MinuteCE®
Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence
1.25 program credits
- Hope S. Rugo, MD, FASCO
- Nadia Harbeck, MD, PhD
1.25 program credits
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
CME/CE
Mastering the Complexity of AML Treatment: A Multidimensional Approach to Diagnosis, Therapy, and Side Effect Management
1.00 credit
- Amir T. Fathi, MD
- Courtney DiNardo, MD
- Brian A. Jonas, MD, PhD
1.00 credit

Programs

Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Project Oncology®
Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
MinuteCE®
Differentiating CDK4/6 Inhibitors in an Evolving European Treatment Landscape for High-Risk HR+/HER2- EBC
1.25 program credits
- Nadia Harbeck, MD, PhD
1.25 program credits
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
Project Oncology®
From MGUS to Multiple Myeloma: Understanding the Progression of Precursor Diseases
- Betsy O'Donnell, MD
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
Project Oncology®
Optimizing the Screening of Precursor Diseases in Multiple Myeloma
- Betsy O'Donnell, MD